Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal ecoplasia

International Journal of Cancer

Volumn 119, Issue 11, 2006, Pages 2651-2656

  Shastri, Yogesh M ^a   Naumann, Marc ^a   Oremek, Gerhard M ^a   Hanisch, Ernst ^b   Rösch, Wolfgang ^c   Mössner, Joachim ^d   Caspary, Wolfgang F ^a   Stein, Jürgen M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Asklepios Hospital   (Germany)

^c Nord West Hospital   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Colorectal cancer screening; Fecal occult blood testing; Pyruvate kinase type M2 (M2 PK)

Indexed keywords

BIOCHEMICAL MARKER; ISOENZYME; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; ENZYME ANALYSIS; FECES ANALYSIS; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OCCULT BLOOD; POPULATION RISK; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33750626736     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22243     Document Type: Article

References (53)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37 (Suppl. 8):S4-S66.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
4. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-8.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
6. Ciccolallo L, Capocaccia R, Coleman MP, Berrino F, Coebergh JW, Damhuis RA, Faivre J, Martinez-Garcia C, Moller H, Ponz DL, Launoy G, Raverdy N, et al. Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut 2005;54:268-73.
7. Lamberti C, Sauerbruch T. Early diagnosis of colorectal tumors. Internist (Berl) 2005;46:401-10.
8. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005;128:192-206.
9. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
10. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-7.
11. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71.
12. Ahlquist DA. Occult blood screening. Obstacles to effectiveness. Cancer 1992;70:1259-65.
13. Lieberman DA. Colon cancer screening. The dilemma of positive screening tests. Arch Intern Med 1990;150:740-4.
14. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002; 315:157-68.
15. Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. Ann Intern Med 1997;126:811-22.
16. Macrae FA, St John DJB. Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 2005;82:891-8.
17. Herzog P, Holtermuller KH, Preiss J, Fischer J, Ewe K, Schreiber HJ, Berres M. Fecal blood loss in patients with colonic polyps: a comparison of measurements with 51chromium-labeled erythrocytes and with the Haemoccult test. Gastroenterology 1982;83:957-62.
18. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
19. Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna MR. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003; 49(6, Part 1):861-7.
20. Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, Roald B. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
21. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, Vellacott K, Moshakis V, Reynolds JR. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000; 46:795-800.
22. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402-8.
23. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 2005;100: 1393-403.
24. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
25. Allison JE. Colon cancer screening guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology 2005; 129:745-8.
26. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14.
27. Woolf SH. A smarter strategy? Reflections on fecal DNA screening for colorectal cancer. N Engl J Med 2004;351:2755-8.
28. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 2001;20: 6891-8.
29. Hardt P, Ngoumou B, Rupp J, Schnell-Kretschmer H, Kloer H. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000;20:4965-8.
30. Hardt P, Mazurek S, Toepler M, Chlierbach P, Retzel R, Igenbrodt E, Loer HU. Faecal tumour M2 pyruvate kinase: in a new, sensitive screening tool for colorectal cancer. Brit J Cancer 2004;91:980-4.
31. Naumann M, Schaum B, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J. Faecal pyruvate kinase type M2-a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr 2004;129: 1806,1807.
32. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 2000;20:4961-4.
33. Haug U, Rothenbacher D, Kloer H-U, Stegmaier C, Bremen H. A promising method for colorectal cancer screening. J Cancer Res Clin Oncol 2004;130, P0792.
34. Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol 2005;23:293-300.
35. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y A. Comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8.
36. Ahlquist DA. Fecal occult blood testing for colorectal cancer. Can we afford to do this? Gastroenterol Clin North Am 1997;26:41-55.
37. Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, Drews M, Herzig KH. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol 2005;40:1493,1494.
38. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Anticancer Res 2003;23:855-7.
39. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9.
40. St John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, Penfold JC. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993;104:1661-8.
41. Zappa M, Castiglione G, Paci E, Grazzini G, Rubeca T, Turco P, Crocetti E, Ciatto S. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience. Int J Cancer 2001;92:151-4.
42. Li S, Wang H, Hu J, Li N, Liu Y, Wu Z, Zheng Y, Wang H, Wu K, Ye H, Rao J. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer 2006;118:3078-83.
43. Hoepffner N, Shastri YM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Aliment Pharmacol Ther 2006;23:145-54.
44. Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AV, Bouvier VM, Caces ER. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005;115:493-6.
45. Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001;4:150-6.
46. Launoy G, Smith TC, Duffy SW, Bouvier V. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer 1997;73:220-4.
47. Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, Sadowski D, Sudduth R, Zuckerman GR, Rockey DC. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000;95: 1331-8.
48. Bond JH. The place of fecal occult blood test in colorectal cancer screening in 2006: the U.S. perspective. Am J Gastroenterol 2006;101:219-21.
49. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003;23:851-3.
50. Vogel T, Driemel C, Hauser A, Hansmann A, Lange S, Jonas M, Moslein G. Comparison of different stool tests for the detection of cancer of the colon. Dtsch Med Wochenschr 2005;130:872-7.
51. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002; 52:8-22.
52. Hixson LJ, Fennerty MB, Sampliner RE, McGee D, Garewal H. Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst 1990;82:1769-72.
53. Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, Lehman GA, Mark DG. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112:24-8.